Abstract: A sulfonamide compound of the formula (I): R1—SO2NHCO—A—X—R2  (I) wherein R1 is alky, alkenyl, alkynyl and the like; A is an optionally substitutedheteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyland 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

Abstract: Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF-&kgr;B is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF-&kgr;B, such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia.

Abstract: A compound of the formula (I): 1

Abstract: Agents for promoting fattening of animals which contain as the active ingredient(s) at least one member selected from among acids originating in hexoses, non-toxic salts thereof and intramolecular esterification products thereof; and a method of promoting fattening by using these agents.

Abstract: A stabilized pharmaceutical composition in lyophilized form comprising:

Abstract: A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by the general formula (I): wherein R1 is a hydrogen atom or an acyl group and R2 and R3 are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and the stabilizer.

Abstract: Preventives and/or remedies for Parkinson's disease and symptoms associating therewith such as anxiety, depression and/or memory disorder which contain as the active ingredient an adenosine A1A2a receptor dual antagonist or salts thereof.

Abstract: The present invention is a compound and pharmaceutical composition comprising a compound of formula (I): wherein R1 is a 4-(lower) alkyl-imidazol-1-yl or a 4,5-di(lower) alkyl-imidazol-1-yl group, R2 is a hydrogen atom or a lower alkyl group, and R3 is a fluorenyl group. The compound of formula (I) includes pharmaceutically acceptable salts: The compound of formula (I) and salts thereof have 5-HT antagonism activity.

Abstract: A novel means for DNA compaction is provided. The object is accomplished by providing a fullerene derivative having 1 to 4 nitrogen-containing hydrophilic side chain(s) or its salt for DNA compaction. DNA compaction can be achieved effectively, and application to gene therapy is also expected.

Abstract: The present invention relates to a compound of the formula [I]: 1

Abstract: A compound of the formula (I) 1

Abstract: The invention provides an agent for the prevention and/or treatment of skin ulcer or bedsore which comprises a nonprostanoid prostaglandin I2 agonist as an active ingredient.

Abstract: A compound of the formula (I): 1

Abstract: The present invention is a method for purifying an enzyme, particularly an acylase, comprising causing selective aggregation and precipitation of a contaminant enzyme, particularly deacetylase, by the use of a surfactant, particularly a cationic surfactant. The present invention is also a method for regenerating an immobilized enzyme carrier, particularly a synthetic adsorbent or ion exchange resin, comprising allowing a protease to act on the immobilized enzyme to remove the enzyme from the carrier, said immobilized enzyme being prepared by binding the enzyme with the carrier and optionally crosslinking the enzymes by the use of a crosslinking agent after binding. Particularly, the present invention is the above-mentioned carrier regeneration method, wherein the carrier has fine pores, and the above-mentioned carrier regeneration method, wherein the enzyme is cephalosporin C acylase.

Abstract: The present invention relates to a compound formula [I]: 1

Abstract: This invention relates to new polypeptide compounds represented by general formula [I]: wherein R1 and R2 are as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on &bgr;-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious disease including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

Abstract: Methods and products that modulate the activity of the human epithelial calcium channel type 2 (hECaC2). Modulation of hECaC2 activity permits control of cellular differentiation and proliferation. Such methods and products may be applied to control hyperplastic skin growth in psoriasis and basal and squamous cell carcinomas or to promote tissue repair. Methods for identifying ligands for hECaC2, as well as methods for identifying hECaC2 polypeptides with functional activity.

Abstract: The present invention provides a new antimicrobial compound WF14573, and a process for producing WF14573 by (a) culturing a WF14573A and/or B-producing microorganism in a nutrient medium and recovering WF14573A and/or B from the resultant cultured broth or (b) deacylating WF14573A and/or B in the presence of a microbial substance which is capable of deacylating WF14573A and/or B. Also provided are an antimicrobial agent comprising WF14573 and carrier(s), a pharmaceutical composition comprising an effective amount of WF14573 and pharmaceutically acceptable carrier(s), a method for killing microorganisms by applying WF14573 to the microorganisms, and use of WF14573 for the treatment of infectious diseases caused by pathogenic microorganisms.

Abstract: Heterobicyclic derivatives of the formula: wherein R1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R2 is aryl which may have suitable substituent(s) or heterocyclic group, and R3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as a medicament.

Abstract: Agents for promoting fattening of animals which contain as the active ingredient(s) at least one member selected from among acids originating in hexoses, non-toxic salts thereof and intramolecular esterification products thereof; and a method of promoting fattening by using these agents.